Interim results of VITOBA(tm) (VImpaT added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology

ATLANTA, April 26, 2012 /PRNewswire/ -- UCB today announced interim results from the VITOBA™ ( VI mpa T ® added to O ne B aseline A ED) study, which showed that patients with less refractory partial-onset seizures treated with Vimpat® (lacosamide) C-V as add-on to monotherapy experienced seizure reduction.  These data were presented today at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans.  VITOBA™ is a six-month prospect...continued UCBJY

URL: http://www.investorpoint.com/news/INTHPINK/50717667/